LIQUICHEK ANTI-RNP CONTROL, EIA, MODEL 207

K984476 · Bio-Rad · LKO · Dec 22, 1998 · Immunology

Device Facts

• Record ID: K984476
• Device Name: LIQUICHEK ANTI-RNP CONTROL, EIA, MODEL 207
• Applicant: Bio-Rad
• Product Code: LKO · Immunology
• Decision Date: Dec 22, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5100
• Device Class: Class 2

Intended Use

Liquichek Anti-RNP Control, EIA is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the detection of ribonucleoprotein (RNP) autoantibodies.

Device Story

Liquichek Anti-RNP Control, EIA is an unassayed quality control serum used in clinical laboratories to monitor the performance of enzyme immunoassay (EIA) procedures for detecting RNP autoantibodies. The device is prepared from human serum supplemented with preservatives (0.1% sodium azide) and stabilizers. It is provided in liquid form at three levels: negative, positive, and high positive. Laboratory personnel use the control to verify the accuracy and precision of immunoassay test kits. By comparing observed results against expected ranges, clinicians ensure the reliability of patient test results, facilitating consistent diagnostic performance for systemic rheumatic diseases.

Clinical Evidence

No clinical data. Bench testing only.

Technological Characteristics

Human serum-based control; contains 0.1% sodium azide preservative; liquid form; stored at 2-8°C; 30-day open-vial stability; three levels (negative, positive, high positive).

Indications for Use

Indicated for use as an unassayed quality control to monitor enzyme immunoassay procedures for the detection of ribonucleoprotein (RNP) autoantibodies in clinical laboratory settings.

Regulatory Classification

Identification

An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).

Predicate Devices

• Helix Enzyme Immunoassay Antinuclear Antibody Screening Test Kit (K954723)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a white background with some small, faint, and blurry dark spots scattered across it. The spots are irregularly shaped and distributed randomly. Due to the lack of distinct features, it is difficult to determine the exact nature or origin of the spots.

Image /page/0/Picture/2 description: The image shows the logo for BIO-RAD. The logo is white text on a black rounded rectangle. The text is in all caps and bolded.

Laboratories

California 92618-20 elembone [phone]

## 510(k) Summary

Submitter Bio-Rad Laboratories 9500 Jeronimo Road Irvine. CA [phone] Fax [phone]

Contact Person Elizabeth Platt

Date of Summary Preparation Pecember 14, 1998

Device (Trade & Common Name) Liquichek Anti-RNP Control, EIA

Classification Name Class II. 82LKO CFR 866.5100: Anti-RNP Antibody, Antigen and Control.

Devices to Which Substantial Equivalence is Claimed Helix Enzyme Immunoassay Antinuclear Antibody Screening Test Kit Helix Diagnostics West Sacrament, California K954723

#### Statement of Intended Use

Liquichek Anti-RNP Control, EIA is intended for use as an unassayed quality control to monitor enzyme immunoassay procedures for the detection of ribonucleoprotein (RNP) autoantibodies.

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for Bio-Rad. The logo is white text on a black, rounded rectangle. The text reads "BIO-RAD" with a plus sign in between the "BIO" and "RAD".

Bio-Rad Laboratories Diagnostics Group 9500 Jeronimo Road Irvine, California 92618-2017 Telephone: [phone]

### Description of the Device

Liquichek Anti-RNP Control, EIA is prepared from human serum with added preservatives and stabilizers. This product is provided in liquid form for convenience. This product contains 0.1% sodium azide as a preservative.

Statement of How Technological Characteristics Compare to Substantial Equivalent Device A table is provided below comparing the similarities between the Bio-Rad Liquichek Anti-RNP Control, EIA and the device to which substantial equivalence is claimed.

| | Helix Enzyme Immunoassay Antinuclear<br>Antibody Screening Test Kit | Bio-Rad Liquichek Anti-RNP<br>Control, EIA |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | A qualitative enzyme immunoassay (EIA) for<br>screening the presence of antinuclear<br>antibodies (ANAs) in human serum as an aid<br>in the diagnosis of certain systemic rheumatic<br>diseases. | An unassayed quality control<br>serum for monitoring enzyme<br>immunoassay procedures for<br>the detection of<br>ribonucleoprotein (RNP)<br>autoantibodies. |
| Form | Liquid | Liquid |
| atrix | Human Serum | Human Serum |
| Levels | Negative, Positive, Cutoff | Negative, Positive, High Positive |
| Storage | 2-8°C | 2-8°C |
| Analytes | Total ANAs against:<br>DNA (dsDNA, nDNA)<br>Histones<br>SS-A/Ro<br>SS-B/La<br>Sm<br>SmRNP<br>Scl-70<br>Jo-1<br>Centrometric antigens<br>Sera positive for Immunofluorescent<br>(IFA) Hep-2 ANAs | Anti-RNP |
| Open Vial<br>Claim | Shelf life | 30 Days at 2-8°C |

{2}------------------------------------------------

Image /page/2/Picture/2 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with three lines forming its body and wings. The eagle is oriented to the right. Encircling the eagle is text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA".

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

DEC 22 1998

Ms. Elizabeth Platt Staff Regulatory Affairs Representative BIO-RAD LABORATORIES 9500 Jeronimo Road Irvine, CA 92618-2017

Re: K984476 Trade Name: Liquichek Anti-RNP Control, EIA Model #207 Regulatory Class: II Product Code: LKO Dated: December 14, 1998 December 16, 1998 Received:

Dear Ms. Platt:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, qood manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

{3}------------------------------------------------

#### Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Putman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page 1 of 1

149844 510(k) Number: J Device Name: Liquichek Anti-RNP Control, EIA

Indications for Use:

Liquichek Anti-RNP Control, EIA is intended for use as an unassayed quality control to Elquieren Inmunoassay procedures for the detection of ribonucleoprotein (RNP) autoantibodies.

# (PLEASE DO NOT WRITE BELOW THE LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

(Concurrence of CDRH, Office of Device Evaluation)

| | <img alt="Signature" src="signature.png"/> |
|---------------|--------------------------------------------|
| | (Division Sign-Off) |
| | Division of Clinical Laboratory Devices |
| 510(k) Number | K984476 |

| Prescription Use | <div> <img alt="Checkmark" src="checkmark.png"/> </div> | OR | Over-The Counter Use |
|------------------|---------------------------------------------------------|----|----------------------|
|------------------|---------------------------------------------------------|----|----------------------|